Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc. (P09)

Market Closed
12 Dec, 20:00
1. 83
-0.15
-7.44%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-1.02 Eps
1.98
Previous Close
Day Range
1.83 1.85
Year Range
0.75 2.27
Want to track P09 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days

Summary

P09 closed Friday lower at €1.83, a decrease of 7.44% from Thursday's close, completing a monthly decrease of -7.56% or €0.15. Over the past 12 months, P09 stock gained 4.58%.
P09 is not paying dividends to its shareholders.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0.02%. On average, the company has surpassed earnings expectations by 0.12%, based on the last three reports. The next scheduled earnings report is due on Feb 12, 2026.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

P09 Chart

Pacific Biosciences (PACB) Upgraded to Buy: Here's Why

Pacific Biosciences (PACB) Upgraded to Buy: Here's Why

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 month ago
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y

PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y

PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.

Zacks | 1 month ago
Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics

Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 month ago

Pacific Biosciences of California, Inc. (P09) FAQ

What is the stock price today?

The current price is €1.83.

On which exchange is it traded?

Pacific Biosciences of California, Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is P09.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 12, 2026.

Has Pacific Biosciences of California, Inc. ever had a stock split?

No, there has never been a stock split.

Pacific Biosciences of California, Inc. Profile

Life Sciences Tools & Services Industry
Healthcare Sector
Christian O. Henry CEO
XDUS Exchange
US69404D1081 ISIN
US Country
575 Employees
- Last Dividend
- Last Split
27 Oct 2010 IPO Date

Overview

Pacific Biosciences of California, Inc., originally known as Nanofluidics, Inc. until its name change in 2005, is a biotechnology firm focused on the design, development, and manufacturing of solutions for sequencing in order to tackle genetically complex problems. Founded in the year 2000 and based in Menlo Park, California, the company has carved a niche for itself in the realm of high-fidelity long-read sequencing technologies. Pacific Biosciences, also known as PacBio, caters to a diverse clienteles such as academic and governmental research institutions, genome centers, public health laboratories, hospitals, clinical research institutes, contract research organizations, as well as entities in the pharmaceutical and agricultural sectors. The company boasts a global presence, marketing its products directly and through distribution partners across Asia, Australia, Europe, the Middle East, Africa, and Latin America. Strategic alliances, like those with Invitae Corporation for development and commercialization, and a collaboration with Radboud University Medical Center for genetics research, are pillars supporting PacBio's innovation and market expansion.

Products and Services

  • Sequencing Systems
  • Pacific Biosciences offers sequencing systems renowned for their single molecule real-time (SMRT) technology. This technology allows for the resolution of genetically complex issues through high-fidelity, long-read sequencing capabilities.

  • Consumable Products
  • The company provides a variety of consumable products for sequencing, including SMRT cells, and reagent kits designed for specific workflows. This includes kits for the preparation of SMRTbell double-stranded DNA libraries, which comprise essential molecular biology reagents necessary for sequencing preparation.

  • Binding and Sequencing Kits
  • PacBio's binding kits include modified DNA polymerase, crucial for binding SMRTbell libraries to the polymerase in preparation for sequencing. Sequencing kits, on the other hand, contain all necessary reagents for on-instrument real-time sequencing, which includes phospholinked nucleotides.

  • Revio System & Sequel Systems
  • The Revio and Sequel systems are designed for the conduct, monitoring, and analysis of single-molecule biochemical reactions in real-time, pioneering advancements in the sequencing technologies sector.

  • Short-Read Sequencing (SBB)
  • Beyond its forte in long-read sequencing, Pacific Biosciences also provides solutions for short-read sequencing (SBB), catering to a broader range of genomic analysis needs.

  • Onso Instrument & SBB Consumables
  • The Onso instrument is tailored for conducting, monitoring, and analyzing SBB biochemical reactions. Accompanying consumables include flow cells and reagent kits for clustering and sequencing, facilitating comprehensive short-read sequencing processes.

Contact Information

Address: 1305 O’Brien Drive
Phone: 650 521 8000